Xilio TherapeuticsXLO
About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Employees: 73
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]
91% more capital invested
Capital invested by funds: $12.6M [Q3] → $24M (+$11.5M) [Q4]
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
18.79% more ownership
Funds ownership: 36.3% [Q3] → 55.09% (+18.79%) [Q4]
3% more funds holding
Funds holding: 33 [Q3] → 34 (+1) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for XLO.
Financial journalist opinion
Based on 7 articles about XLO published over the past 30 days
